AI Insight
This commentary discusses the optimization of late-line systemic therapy for patients with chemo-refractory metastatic colorectal cancer. The authors emphasize that treatment decisions must carefully balance expected therapeutic benefits against quality of life impacts, including adverse events, hospital visits, and psychosocial consequences. A comprehensive individualized assessment should consider patients' performance status, cumulative disease burden, previous treatment toxicities, and declining organ function reserves.
Why it matters
This article provides important guidance for oncologists managing advanced colorectal cancer patients who have exhausted standard treatment options. It highlights the need for personalized decision-making that prioritizes patient quality of life alongside survival outcomes in late-stage disease management.
Understand the Science
Offering late-line systemic therapy to patients with chemo-refractory metastatic colorectal cancer demands a careful estimation of the balance between the expected treatment benefit and its potential impact on quality of life, including adverse events, hospital visits, and psychosocial consequences.1 In such a comprehensive and individualised assessment of patients’ general conditions, usually summarised by Eastern Cooperative Oncology Group (ECOG) performance status, the cumulative burden of disease-related symptoms and previous treatment-related adverse events, together with the potential decay of organ functional reserve, cannot be neglected.